Clinical trials: Optic Nerve Pathology
Progressive Supranuclear Palsy
Test-retest Study With [18F]PI-2620 in PSP-RS and NDC
The overall goal of this protocol is to evaluate the imaging characteristics of [18F]PI-2620 using positron emission tomography (PET) in patients with progressive supranuclear palsy, Richardson's syndrome (PSP-RS)
- Trial name
- NCT05187546
- Testing
- [18F]-PI2620
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Life Molecular Imaging GmbH
Rare Diseases, Neuromyelitis Optica Spectrum Disorder (NMOSD)
Epidemiological Study of Treatment Approaches on AQP4-IgG Positive NMOSD in Russia
This is a multi-centre, retrospective-prospective, single-arm, non-interventional (observational) cohort study with secondary data collection within real-world settings of participants with AQP4-IgG positive NMOSD.
- Trial name
- NCT07247292
- Where
- Russia
- Volunteers
- 3 people
- Sponsor
- AstraZeneca
Uveal Melanoma
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma
- Trial name
- NCT05907954
- Testing
- Darovasertib
- Where
- 18 sites in United States, Australia and 5 more
- Volunteers
- 160 people
- Sponsor
- IDEAYA Biosciences
Progressive Supranuclear Palsy
RT001 in Patients With Progressive Supranuclear Palsy (PSP) PROGRESSIVE SUPRANUCLEAR PALSY
This is a randomized, placebo-controlled trial of RT001 in patients with PSP.
- Trial name
- NCT04937530
- Testing
- RT001
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Biojiva LLC
Leber Hereditary Optic Neuropathy (Optic, Atrophy, Hereditary, Leber)
EAP_GS010_single Patient
Expanded Access Use for a single patient of Bilateral Intravitreal Injection of GS010 in a Single Subject Affected with G11778A ND4 Leber Hereditary Optic Neuropathy
- Trial name
- NCT03672968
- Testing
- GS010
- Sponsor
- GenSight Biologics
Binocular Vision Disorder, Convergence Insufficiency
Neurolens Headache Study
To understand the benefits of the neurolens Measurement Device and neurolens treatment as it pertains to treating symptoms related to Chronic Headaches.
- Conditions
- Binocular Vision Disorder, Convergence Insufficiency, Headache, Computer Vision Syndrome
- Trial name
- NCT05070767
- Testing
- Neurolens spectacle lens
- Where
- 10 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Neurolens Inc.
Multiple Sclerosis, NMO Spectrum Disorder
Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study.
The RECLAIM study aims to gather a centralized and harmonized dataset, enabling the secondary use of data for building AI-based models that will support diagnosis and prognosis of individual Multiple Sclerosis patient's disease…
- Conditions
- Multiple Sclerosis, NMO Spectrum Disorder, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Radiologically Isolated Syndrome
- Trial name
- RECLAIM (NCT06280755)
- Where
- 3 sites in Czechia, Germany
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- icometrix
Neoplasms
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
To assess the safety and tolerability at increasing dose levels of PF-04518600 alone or in combination wtih PF-05082566 in patients with select advanced or metastatic carcinoma in order to determine the maximum tolerated dose and…
- Trial name
- NCT02315066
- Testing
- PF-04518600, PF-04518600 plus PF-05082566
- Where
- 30 sites in United States, France and 2 more
- Volunteers
- 174 people
- Sponsor
- Pfizer
Amblyopia, Ocular Motility Disorders
A New Approach to Vision Therapy Based on Naturalistic 3-D Computer Gaming
The research team will execute two concurrent studies within a common framework. The first will compare iCare to standard of care occlusion therapy (patching) for amblyopia in patients ages 4 to 18 (inclusive).
- Trial name
- ICARE (NCT03066063)
- Testing
- iCare, Amblyopia standard of Care, CI standard of Care
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Barron Associates, Inc.
Optic Neuritis
Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research
The goal of this clinical trial is to evaluate the safety and efficacy of privosegtor, a neuroprotective candidate, in patients diagnosed with optic neuritis (ON).
- Trial name
- PIONEER-1 (NCT07623668)
- Testing
- Privosegtor, Methylprednisolone
- Where
- 4 sites in United States
- Volunteers
- 210 people
- Sponsor
- Oculis
Progressive Supranuclear Palsy
A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP)
The purpose of the study is to assess the safety and tolerability of UCB0107 in study participants with Progressive Supranuclear Palsy (PSP).
- Trial name
- NCT04185415
- Testing
- bepranemab
- Where
- 13 sites in Belgium, Germany and 2 more
- Volunteers
- 25 people
- Sponsor
- UCB Biopharma SRL
Melanoma Metastatic, Melanoma of Skin
Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
Why the research is needed: Researchers are looking for a better way to treat melanoma that has spread or cannot be removed surgically.
- Conditions
- Melanoma Metastatic, Melanoma of Skin, Melanoma BRAF V600E/K Mutated, Melanoma Recurrent
- Trial name
- NCT06784648
- Testing
- pembrolizumab (KEYTRUDA®), BI-1607, Ipilimumab (YervoyTM, 50 mg/10 mL solution)
- Where
- 4 sites in Germany, Spain and 1 more
- Volunteers
- 35 people
- Sponsor
- BioInvent International AB
Progressive Supranuclear Palsy
Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy
The purpose of the study is to evaluate the safety and efficacy of davunetide for the treatment of Progressive Supranuclear Palsy.
- Trial name
- NCT01110720
- Testing
- Davunetide
- Where
- 48 sites in United States, Australia and 4 more
- Volunteers
- 313 people
- Sponsor
- Allon Therapeutics
Melanoma (Skin), Melanoma Stage IV
Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy
The study hypothesis is that new imaging agents [203Pb]VMT01 and [68Ga]VMT02 can be safely used in humans without independent biological effect and can be used to image melanoma tumors expressing the melanocortin sub-type 1…
- Conditions
- Melanoma (Skin), Melanoma Stage IV, Melanoma, Uveal, Melanoma, Mucosal
- Trial name
- TIMAR1 (NCT04904120)
- Testing
- [203Pb]VMT01, [68Ga]VMT02
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Perspective Therapeutics
SLE, Sclerosis
A Study of RD06-04 in Patients With Active Autoimmune Diseases
This is an open-label, Phase I, investigator-initiated trial (IIT) aimed at evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RD06-04 in patients with autoimmune diseases mediated by…
- Conditions
- SLE, Sclerosis, ANCA Associated Vasculitis, IIM
- Trial name
- NCT06548620
- Testing
- RD06-04 cell infusion
- Where
- China
- Sponsor
- Nanjing Bioheng Biotech Co., Ltd.
Progressive Supranuclear Palsy (PSP)
An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)
The purpose of this study was to assess the long-term safety and efficacy of ABBV-8E12 (tilavonemab) in participants with progressive supranuclear palsy (PSP).
- Trial name
- NCT03391765
- Testing
- ABBV-8E12
- Where
- 42 sites in United States, Australia and 3 more
- Volunteers
- 142 people
- Sponsor
- AbbVie
Progressive Supranuclear Palsy, Corticobasal Degeneration
A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary Tauopathies
This is a phase II study intended to evaluate the safety, tolerability and pharmacodynamics of NIO752 in participants with primary tauopathies.
- Conditions
- Progressive Supranuclear Palsy, Corticobasal Degeneration, Frontotemporal Lobar Degeneration, Tauopathies
- Trial name
- NCT07868328
- Testing
- NIO752
- Volunteers
- 48 people
- Sponsor
- Novartis Pharmaceuticals
Progressive Supranuclear Palsy
Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy
The purpose of this study is to evaluate the safety and tolerability of multiple ascending intravenous infusions of BMS-986168 and to assess the pharmacokinetics and immunogenicity of BIIB092, and pharmacodynamics of BIIB092 on…
- Trial name
- CN002-003 (NCT02460094)
- Testing
- BIIB092
- Where
- 13 sites in United States
- Volunteers
- 48 people
- Sponsor
- Biogen
Advanced Solid Tumors
Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors
This study will test a Regeneron drug called REGN13089-M404-M2980 ("study drug") to see if it can help treat previously treated, advanced solid tumors (tumors that have grown and spread to different areas of the body).
- Trial name
- NCT07863024
- Testing
- REGN13089-M404-M2980
- Volunteers
- 320 people
- Sponsor
- Regeneron Pharmaceuticals
Intraocular Melanoma, Melanoma (Skin)
Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma
RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Intraocular Melanoma, Melanoma (Skin), Metastatic Cancer
- Trial name
- NCT00324727
- Testing
- melphalan, regional chemotherapy, systemic chemotherapy
- Where
- 12 sites in United States
- Volunteers
- 93 people
- Sponsor
- Delcath Systems Inc.